Clinical Trials
9 trialsNCT01990209 2022-06-30
Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)
SCRI Development Innovations, LLC
Phase 2 Completed
NCT01816048 2019-12-09
NaF Positron Emission Tomography/Computed Tomography (PET/CT)Imaging to Assess Treatment Responsiveness to TAK-700 in Patients With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastasis
University of Wisconsin, Madison
Phase 2 Terminated
NCT01808040 2019-11-18
A Phase 1b Study of TAK-700 in Postmenopausal Women With Hormone-receptor Positive Metastatic Breast Cancer
University of Wisconsin, Madison
Phase 1 Completed
NCT01707966 2019-05-15
Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel Therapy
Swiss Cancer Institute
Phase 3 Completed
NCT02053311 2018-07-30
Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents
Swiss Cancer Institute
Phase 3 Withdrawn
NCT02101684 2018-03-05
Greko II
Grupo EspaƱol de Tumores HuƩrfanos e Infrecuentes
Phase 2 Terminated
NCT01866423 2017-08-31
Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
University of Southern California
Phase 2 Terminated
NCT03211052 2017-07-07
NEPTUNE
Queen Mary University of London
Phase 2 Terminated
NCT02054793 2014-07-23
Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itraconazole In Men With Castration-Resistant Prostate Cancer (CRPC)
Johns Hopkins University
Phase 1/2 Withdrawn